论文部分内容阅读
目的评价经皮冠状动脉介入治疗(PCI)之前使用曲美他嗪对冠心病伴糖尿病患者术中及术后心肌缺血程度的影响。方法对确诊糖尿病合并心绞痛准备行PTCA术134例患者随机分为术前口服曲美他嗪实验组和对照组,进行相关对比研究。结果球囊充气时平均ST段抬高或降低实验组低于对照组,充气到ST段抬高或减低的时间、充气到发生心绞痛的平均时间实验组高于对照组,放气到心绞痛缓解的平均时间实验组低于对照组,术后实验组CK-MB、TNI、CRP低于对照组,以上比较均有显著性差异。结论术前口服曲美他嗪可提高冠心病合并糖尿病患者对心肌缺血的耐受程度,并有助于术中减少心绞痛的发生,提高手术的安全性,减少术后心肌缺血的发生。
Objective To evaluate the effect of trimetazidine on myocardial ischemia in patients with coronary heart disease and diabetes mellitus before percutaneous coronary intervention (PCI). Methods 134 patients with diagnosed diabetes mellitus and angina pectoris for PTCA were randomly divided into preoperative oral trimetazidine experimental group and control group, and the related comparative studies were conducted. Results When the balloon was inflated, the average ST segment elevation or decreased in the experimental group was lower than that in the control group, the time from inflated to the ST segment elevation or decrease, the average time from inflated to angina pectoris in the experimental group was higher than that in the control group, The average time in the experimental group was lower than that in the control group. The postoperative CK-MB, TNI and CRP in the experimental group were lower than those in the control group, all of which were significantly different. Conclusion Preoperative oral trimetazidine can improve the degree of myocardial ischemic tolerance in patients with coronary heart disease complicated with diabetes, and help to reduce the incidence of angina pectoris, improve the safety of surgery and reduce the incidence of postoperative myocardial ischemia.